In this episode we unpack the shift from Research Use Only (RUO) peptides to the emerging Physician Use Only (PUO) label.
At first glance, PUO might look like a move toward a more legitimate, physician-driven distribution model. But a closer look suggests something more complex.
PUO is not an FDA regulatory category and does not automatically place peptides inside licensed pharmacy frameworks such as 503A or 503B compounding. Instead, it appears to function primarily as a liability repositioning strategy, allowing vendors to distance themselves from direct human use claims while shifting more responsibility toward physicians and clinics.
We explore how the original RUO label emerged, why that model began to break down, and how some vendors are now rebranding products for “physician use” while still operating outside formal drug approval pathways.
The episode also looks at real examples from companies marketing peptides to clinicians while still including research-use disclaimers , creating a hybrid system where the marketing suggests therapeutic use but the legal framework remains unchanged.
The key takeaway: PUO may change the language around peptides, but it does not necessarily change the underlying regulatory structure.
And while RUO vendors rebrand, a parallel system built around telehealth and compounding pharmacies may be emerging at the same time.
Comments